New biosensor for detecting active tuberculosis
en-GBde-DEes-ESfr-FR

New biosensor for detecting active tuberculosis


A research team at UPV is leading the development of a sensor that paves the way for the rapid, selective and cost-effective detection of active tuberculosis. The device detects the presence of a protein secreted by Mycobacterium tuberculosis, the bacterium that causes the disease. It provides results in just 60 minutes – significantly less time than conventional methods, such as microbiological culture, which can take several weeks.

Tuberculosis remains one of the world's major public health problems today. According to the World Health Organisation's 2024 global report, it has once again become the leading cause of death from a single infectious agent. "Therefore, having tools that enable early and reliable diagnosis is key to curbing its transmission," emphasises Dr Isabel Caballos, a member of the IDM-UPV team.

Fluorescent detection

The new system is based on a nanoporous material containing a fluorescent molecule and coated with an antibody specific to the MPT64 protein, a characteristic marker of active tuberculosis. When this protein is present, the antibody that blocks the pores of the material shifts, releasing the fluorescent compound. This light signal allows the infection to be detected easily.

"One of the main innovations of the biosensor is that it detects active disease, which is particularly significant because other molecular techniques, such as PCR, can identify fragments of bacterial DNA without distinguishing whether the infection is active, past or latent. In contrast, this system recognises a protein secreted by the bacterium during active infection, providing more accurate information from a clinical perspective," notes Professor Ramón Martínez Máñez, head of the NANOSENS group at IDM-UPV and the Joint Unit for Nanomedicine and Sensors at IIS La Fe.

A promising pathway to improve tuberculosis diagnosis

The trials carried out show that the biosensor achieves a very low detection limit and high selectivity against proteins from other respiratory pathogens, such as influenza viruses, SARS-CoV-2, respiratory syncytial virus, and other non-tuberculous mycobacteria. In addition, the device was validated using cultured clinical samples from patients.

"In the final validation we conducted with 20 cultures of respiratory samples from tuberculosis patients, the system achieved a sensitivity of 80% and a specificity of 90%, with good predictive values, confirming its potential as a diagnostic tool," notes Dr Ana Gil, from the Microbiology Department at the Hospital Universitari i Politècnic La Fe in Valencia.

According to researchers at IDM-UPV, this new biosensor offers a promising avenue for improving tuberculosis diagnosis, particularly in resource-poor countries, where access to advanced techniques remains a challenge. "Its simplicity, portability and selective detection capability make it a tool with great potential to contribute to the control of a disease that remains one of the deadliest in the world," concludes Professor Elena Aznar, a professor at the UPV and a researcher at CIBER-BBN and the IIS La Fe.

The study, published in the journal Talanta, was led by the Inter-University Institute for Molecular Recognition and Technological Development (IDM) at the Universitat Politècnica de València and the Universitat de València. It also involved the UPV-IIS La Fe Joint Research Unit on Nanomedicine and Sensors, the CIBER Centre for Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), the UPV-CIPF Joint Research Unit for Disease Mechanisms and Nanomedicine, and the Microbiology Department and the Severe Infection Group at Hospital Universitari i Politècnic La Fe.

Reference

Caballos I, Hernández-Montoto A, Climent E, Gil-Brusola A, Martínez-Máñez R, Aznar E. Targeted detection of Mycobacterium tuberculosis MPT64 antigen using an antibody-coated nanoporous anodic alumina biosensor: A novel approach for tuberculosis screening. Talanta. 2026;305:129625. doi:10.1016/j.talanta.2026.129625
Archivos adjuntos
  • UPV's Lab
  • Research team
Regions: Europe, Spain
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement